The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis

Annals of the Rheumatic Diseases

Volumn 72, Issue 5, 2013, Pages 686-693

  Lazarevic, Dragana ^a   Pistorio, Angela ^a   Palmisani, Elena ^a   Miettunen, Paivi ^a   Ravelli, Angelo ^a,b   Pilkington, Clarissa ^c   Wulffraat, Nico M ^d   Malattia, Clara ^b   Garay, Stella Maris ^e   Hofer, Michael ^f   Quartier, Pierre ^g   Dolezalova, Pavla ^h   Penades, Inmaculada Calvo ⁱ   Ferriani, Virginia P L ^j   Ganser, Gerd ^k   Kasapcopur, Ozgur ^l   Melo Gomes, Jose Antonio ^m   Reed, Ann M ⁿ   Wierzbowska, Malgorzata ^o   Rider, Lisa G ^p   Martini, Alberto ^a,b   Ruperto, Nicolino ^a   more..

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e Hospital de Ninos Sor Maria Ludovica   (Argentina)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h CHARLES UNIVERSITY   (Czech Republic)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^j UNIVERSITY OF SÃO PAULO   (Brazil)

^k Abt Kinder und Jugendrheumatologie   (Germany)

^l ISTANBUL UNIVERSITY   (Turkey)

^m INSTITUTO PORTUGUÊS DE REUMATOLOGIA   (Portugal)

ⁿ MAYO CLINIC   (United States)

^o INSTITUTE OF RHEUMATOLOGY   (Poland)

^p NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE;

ACCURACY; ARTICLE; CHILD; CHILDHOOD MYOSITIS ASSESSMENT SCALE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CRITERION VARIABLE; DATA BASE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; ENDURANCE; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH CARE ORGANIZATION; HEALTH STATUS; HUMAN; JUVENILE DERMATOMYOSITIS; MAJOR CLINICAL STUDY; MALE; MANUAL MUSCLE TESTING; MUSCLE CONTRACTION; MUSCLE STRENGTH; MYOSITIS DISEASE ACTIVITY ASSESSMENT VISUAL ANALOGUE SCALE; PEDIATRIC RHEUMATOLOGY INTERNATIONAL TRIALS ORGANISATION; PHYSICIAN GLOBAL ASSESSMENT OF OVERALL DISEASE ACTIVITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; VISUAL ANALOG SCALE;

ADRENAL CORTEX HORMONES; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DERMATOMYOSITIS; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE STANDARDS; RHEUMATOLOGY; SENSITIVITY AND SPECIFICITY;

EID: 84875960380     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201483     Document Type: Article

References (48)

1. Huber A, Feldman BM. Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheumatol Rep 2005;7:441-6.
2. Ravelli A, Trail L, Ferrari C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 2010;62:63-72.
3. Kim S, El-Hallak M, Dedeoglu F, et al. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum 2009;60:1825-30.
4. Rider LG, Lachenbruch PA, Monroe JB, et al.; IMACS Group. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009;60:3425-35.
5. Feldman BM, Rider LG, Reed AM, et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008;371:2201-12. (Pubitemid 351890413)
6. Hasija R, Pistorio A, Ravelli A, et al. Approaches for the treatment of new onset and flared juvenile dermatomyositis: an international multicenter PRINTO study. Arthritis Rheum 2011;63:3142-52.
7. Sanner H, Kirkhus E, Merckoll E, et al. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case-control study. Arthritis Care Res (Hoboken) 2010;62:1103-11.
8. Sanner H, Gran JT, Sjaastad I, et al. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 2009;48:1541-7.
9. Oddis CV, Rider LG, Reed AM, et al.; International Myositis Assessment and Clinical Studies Group. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005;52:2607-15. (Pubitemid 41369088)
10. Huber AM, Lang B, LeBlanc CM, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000;43:541-9. (Pubitemid 30394944)
11. Ruperto N, Martini A. Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO). Arch Dis Child 2011;96:596-601.
12. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
13. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
14. Ruperto N, Ravelli A, Pistorio A, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008;59:4-13. (Pubitemid 351171873)
15. Rider LG, Feldman BM, Perez MD, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1997;40:1976-83. (Pubitemid 27494657)
16. Lovell DJ, Lindsley CB, Rennebohm RM, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1999;42:2213-19. (Pubitemid 30263608)
17. Rennebohm RM, Jones K, Huber AM, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. Arthritis Rheum 2004;51:365-70. (Pubitemid 38725134)
18. Huber AM, Feldman BM, Rennebohm RM, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004;50:1595-603. (Pubitemid 38608082)
19. Rider LG, Koziol D, Giannini EH, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2010;62:465-72.
20. Bode RK, Klein-Gitelman MS, Miller ML, et al. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003;49:7-15. (Pubitemid 36286124)
21. Singh G, Athreya BH, Fries JF, et al. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37:1761-9. (Pubitemid 24371878)
22. Ruperto N, Ravelli A, Pistorio A, et al.; Paediatric Rheumatology International Trials Organisation. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol 2001;19(4 Suppl 23):S1-9.
23. Huber AM, Hicks JE, Lachenbruch PA, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol 2001;28:1106-11. (Pubitemid 32422597)
24. Apaz MT, Saad-Magalhães C, Pistorio A, et al.; Paediatric Rheumatology International Trials Organisation. Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum 2009;61:509-17.
25. Landgraf JM, Abetz L, Ware JE. The CHQ User's Manual. First Edition. Boston, MA: The Health Institute, New England Medical Center, 1996.
26. Isenberg DA, Allen E, Farewell V, et al.; International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004;43:49-54. (Pubitemid 38088368)
27. Guzmán J, Petty RE, Malleson PN. Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes. J Rheumatol 1994;21:739-43. (Pubitemid 24126775)
28. Rider LG, Miller FW. Laboratory evaluation of the inflammatory myopathies. Clin Diagn Lab Immunol 1995;2:1-9.
29. Rider LG, Prasad K, Feldman BM, et al. Relationships among laboratory tests and global disease activity assessments in juvenile dermatomyositis. Arthritis Rheum 1996;39(Suppl):S191.
30. Rider LG. Assessment of disease activity and its sequelae in children and adults with myositis. Curr Opin Rheumatol 1996;8:495-506. (Pubitemid 27044437)
31. Ramanan AV, Feldman BM. The role of muscle enzymes in JDM. Pediatr Rheumatol Online J 2005;3:1-4.
32. Ruperto N, Ravelli A, Cuttica R, et al.; Pediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Arthritis Rheum 2005;52:2854-64. (Pubitemid 41369116)
33. Sultan SM, Allen E, Cooper RG, et al. Interrater reliability and aspects of validity of the myositis damage index. Ann Rheum Dis 2011;70:1272-6.
34. Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31: 2290-4. (Pubitemid 39453253)
35. Wallace CA, Giannini EH, Huang B, et al.; Childhood Arthritis Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Paediatric Rheumatology International Trials Organisation. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011;63:929-36.
36. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Academic Press, 1977.
37. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74. (Pubitemid 8054849)
38. Naji P, Shahram F, Nadji A, et al. Effect of early treatment in polymyositis and dermatomyositis. Neurol India 2010;58:58-61.
39. Na SJ, Kim SM, Sunwoo IN, et al. Clinical characteristics and outcomes of juvenile and adult dermatomyositis. J Korean Med Sci 2009;24:715-21.
40. Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 2008;58:3585-92.
41. Váncsa A, Ponyi A, Constantin T, et al. Pregnancy outcome in idiopathic inflammatory myopathy. Rheumatol Int 2007;27:435-9. (Pubitemid 46294984)
42. Mielnik P, Wiesik-Szewczyk E, Olesinska M, et al. Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies. Autoimmunity 2006;39:243-7. (Pubitemid 43879037)
43. Chowdhary V, Wakhlu A, Agarwal A, et al. Outcome in juvenile dermatomyositis. Indian Pediatr 2002;39:931-5.
44. Fisler RE, Liang MG, Fuhlbrigge RC, et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002;47:505-11.
45. Ruperto N, Pistorio A, Ravelli A, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010;62:1533-41.
46. Foell D, Wulffraat N, Wedderburn LR, et al.; Paediatric Rheumatology International Trials Organization (PRINTO). Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010;303:1266-73.
47. Filocamo G, Davì S, Pistorio A, et al. Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. J Rheumatol 2010;37:1534-41.
48. Rider LG, Giannini EH, Brunner HI, et al.; International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004;50:2281-90. (Pubitemid 38924407)